12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

Mauro,M.J. (2006) Defining and managing imatinib resistance. Hematology.Am.Soc.Hematol.Educ.Program.,
219-225.
O'Hare,T., Eide,C.A., & Deininger,M.W. (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road
to a cure for chronic myeloid leukemia. Blood, 110, 2242-2249.
Marin, D., et al. "European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with
CML in early chronic phase treated with imatinib whose eventual outcome is poor." Blood 112.12 (2008): 4437-
44.
Interferonbehandling versus kemoterapi
Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials:
Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst, 89: 1616-1620, 1997.
Gale, R.P., Hehlmann, R., Zhang, M.J., Hasford, J., Goldman, J.M., Heimpel, H., Hochhaus, A., Klein, J.P., Kolb,
H.J., McGlave, P.B., Passweg, J.R., Rowlings, P.A., Sobocinski, K.A., and Horowitz, M.M. Survival with bone
marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML
Study Group. Blood, 91: 1810-1819, 1998.
Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.L., Maloisel, F., Bouabdallah, R., Guyotat, D.,
Cheron, N., Nicolini, F., Abgrall, J.F., and Tanzer, J. Interferon alfa-2b combined with cytarabine versus
interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J
Med, 337 : 223-229, 1997.
Interferonbehandling før HCT
Morton, A.J., Gooley, T., Hansen, J.A., Appelbaum, F.R., Bruemmer, B., Bjerke, J.W., Clift, R., Martin, P.J.,
Petersdorf, E.W., Sanders, J.E., Storb, R., Sullivan, K.M., Woolfrey, A., and Anasetti, C. Association between
pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic
myelogenous leukemia in chronic phase. Blood, 92: 394-401, 1998.
Autolog HCT
Bhatia, R., Verfaillie, C.M., Miller, J.S., and McGlave, P.B. Autologous transplantation therapy for chronic
myelogenous leukemia. Blood, 89: 2623-2634, 1997.
HCT med søskendedonor
van Rhee, F., Szydlo, R.M., Hermans, J., Devergie, A., Frassoni, F., Arcese, W., de Witte, T., Kolb, H.J.,
Niederwiser, D., Jacobsen, N., Gahrton, G., Bandini, G., Carreras, E., Bacigalupo, A., Michallet, M., Ruutu, T.,
Reiffers, J., Goldman, J.M., Apperley, J., and Gratwohl, A. Long-term results after allogeneic bone marrow
transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working
Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant, 20: 553-560,
1997.
Radich,J.P., Gooley,T., Bensinger,W., Chauncey,T., Clift,R., Flowers,M., Martin,P., Slattery,J., Sultan,D., &
Appelbaum,F.R. (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a
targeted busulfan and cyclophosphamide preparative regimen. Blood, 102, 31-35.
HCT med MUD
Davies, S. M., DeFor, T. E., McGlave, P. B., Miller, J. S., Verfaillie, C. M., Wagner, J. E., and Weisdorf, D. J.
Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically
matched bone marrow from related or unrelated donors. Am.J.Med., 110: 339-346, 2001.
57